Anti-LYPD3/ C4.4A monoclonal antibody

Anti-LYPD3/ C4.4A antibody for FACS & in-vivo assay

Target products collectionGo to LYPD3/LYPD3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0784-Ab-1/ GM-Tg-hg-MP0784-Ab-2Anti-Human LYPD3 monoclonal antibodyHuman
GM-Tg-rg-MP0784-Ab-1/ GM-Tg-rg-MP0784-Ab-2Anti-Rat LYPD3 monoclonal antibodyRat
GM-Tg-mg-MP0784-Ab-1/ GM-Tg-mg-MP0784-Ab-2Anti-Mouse LYPD3 monoclonal antibodyMouse
GM-Tg-cynog-MP0784-Ab-1/ GM-Tg-cynog-MP0784-Ab-2Anti-Cynomolgus/ Rhesus macaque LYPD3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0784-Ab-1/ GM-Tg-felg-MP0784-Ab-2Anti-Feline LYPD3 monoclonal antibodyFeline
GM-Tg-cang-MP0784-Ab-1/ GM-Tg-cang-MP0784-Ab-2Anti-Canine LYPD3 monoclonal antibodyCanine
GM-Tg-bovg-MP0784-Ab-1/ GM-Tg-bovg-MP0784-Ab-2Anti-Bovine LYPD3 monoclonal antibodyBovine
GM-Tg-equg-MP0784-Ab-1/ GM-Tg-equg-MP0784-Ab-2Anti-Equine LYPD3 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0784-Ab-1/ GM-Tg-hg-MP0784-Ab-2; GM-Tg-rg-MP0784-Ab-1/ GM-Tg-rg-MP0784-Ab-2;
GM-Tg-mg-MP0784-Ab-1/ GM-Tg-mg-MP0784-Ab-2; GM-Tg-cynog-MP0784-Ab-1/ GM-Tg-cynog-MP0784-Ab-2;
GM-Tg-felg-MP0784-Ab-1/ GM-Tg-felg-MP0784-Ab-2; GM-Tg-cang-MP0784-Ab-1/ GM-Tg-cang-MP0784-Ab-2;
GM-Tg-bovg-MP0784-Ab-1/ GM-Tg-bovg-MP0784-Ab-2; GM-Tg-equg-MP0784-Ab-1/ GM-Tg-equg-MP0784-Ab-2
Products NameAnti-LYPD3 monoclonal antibody
Formatmab
Target NameLYPD3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LYPD3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-902Pre-Made Lupartumab Amadotin Biosimilar, Whole Mab Adc, Anti-Lypd3 Antibody: Anti-C4.4A therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-329Pre-Made Lupartumab biosimilar, Whole mAb ADC, Anti-LYPD3 Antibody: Anti-C4.4A therapeutic antibody
    Target AntigenProducts DevelopingMulti-species LYPD3/ C4.4A VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0784
    Target NameLYPD3
    Gene ID27076,72434,60378,718197,484471,101081346,513150,100070126
    Gene Symbol and Synonyms2310061G07Rik,C4.4A,LYPD3
    Uniprot AccessionO95274,O55162
    Uniprot Entry NameLYPD3_HUMAN,LYPD3_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, INN Index
    DiseaseN/A
    Gene EnsemblENSG00000124466
    Target ClassificationN/A

    The target: LYPD3, gene name: LYPD3, also named as C4.4A. Predicted to enable laminin binding activity. Predicted to act upstream of or within cell-matrix adhesion. Located in extracellular space. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.